Contribute Try STAT+ Today

Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment believe the medication will be effective, but have concerns about the regulatory process used to endorse the drug and are divided over whether the drug is fairly priced at $56,000 a year, according to a new survey from STAT and The Harris Poll.

The responses underscore that the Food and Drug Administration approval this month of the drug, called Aduhelm, has proven divisive among a wide array of experts, and the poll shows the same is true for the U.S. public. Among those who had only heard about the approval, slightly more than half agree the drug will be effective, but were concerned about the FDA process.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment